Clinical trials: Letrozole
Breast Cancer
Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Breast Cancer Patients
Endocrine therapy is the mainstay of systemic treatment in patients with endocrine responsive breast cancer. Aromatase inhibitors are the most active agents in post-menopausal women.
- Trial name
- NCT00954135
- Testing
- letrozolo+cyclophosphamide, letrozolo+sorafenib+cyclophosphamide
- Where
- 2 sites in Italy
- Volunteers
- 190 people
- Sponsor
- University of Turin, Italy
Healthy Volunteers
Letrozole Treatment in Normal and GnRH Deficient Women
This research study involves the use of the drugs Letrozole, GnRH, and NAL-GLU GnRH antagonist. Letrozole is a drug that is approved by the U.S.
- Trial name
- NCT00351416
- Testing
- Letrozole, NAL-GLU GnRH antagonist
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Metastatic Breast Cancer
Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer
Phase IV trial to investigate the effect of the combination of Letrozole with trastuzumab in metastatic breast cancer patients
- Trial name
- eLEcTRA (NCT00171847)
- Testing
- Letrozole, Trastuzumab plus Letrozole
- Where
- Germany
- Volunteers
- 93 people
- Sponsor
- Novartis Pharmaceuticals
Miscarriage in First Trimester, Missed Miscarriage
Letrozole Plus Misoprostol Versus Misoprostol Alone for Treating Women With Missed Miscarriage
The goal of this clinical trial is to learn whether adding the medicine letrozole to Misoprostol helps women have a complete abortion more often than using Misoprostol alone for the treatment of missed miscarriage (when a…
- Trial name
- NCT07160855
- Testing
- Misoprostol (given vaginally), Letrozole 5 mg
- Where
- Pakistan
- Volunteers
- 92 people
- Sponsor
- Nishtar Medical University
Metastatic Breast Cancer
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic
The purpose of this study is to find out what effect the combination of letrozole (brand name: Femara) and dasatinib (brand name: Sprycel) has on metastatic breast cancer compared to letrozole alone
- Trial name
- NCT00696072
- Testing
- Dasatinib, Letrozole
- Where
- 27 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Breast Cancer
Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment
The course of the disease in female patients with metastatic mammary carcinoma can vary greatly. In this connection, the individual prognosis depends on a complex interaction of tumor- and patient-related factors.
- Trial name
- NCT00241046
- Testing
- Letrozole
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Breast Cancer
Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer
This is a prospective, single-arm, multi-center clinical study of pyrotinib in combination With letrozole in patients With HER2-Positive, ER-Positive metastatic breast cancer.
- Trial name
- NCT04407988
- Testing
- Pyrotinib Maleate plus Letrozole
- Where
- China
- Volunteers
- 86 people
- Sponsor
- Hunan Cancer Hospital
Metastatic Breast Cancer
Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
Everolimus has been approved to be effective when used with exemestane after progression on non-steroidal aromatase inhibitors in postmenopausal women based on the BOLERO-2 clinical trial.
- Trial name
- MIRACLE (NCT02313051)
- Testing
- Everolimus, Goserelin, Letrozole
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese Academy of Medical Sciences
Solid Tumours
To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer
This is an open-label 2-part Phase I study in patients with advanced solid tumours. Part A of the study (mandatory) will assess the effect of olaparib on the pharmacokinetics (PK) of anastrozole, letrozole and tamoxifen and vice…
- Trial name
- NCT02093351
- Testing
- Olaparib, Tamoxifen, Anastrozole
- Where
- 14 sites in Belgium, Denmark and 3 more
- Volunteers
- 79 people
- Sponsor
- AstraZeneca
Infertility, Female
Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome
Polycystic ovary syndrome accounts for the vast majority of anovulatory symptoms and hyperandrogenism in women. The diagnosis of Polycystic ovary syndrome has life-long implications, with increased risk for infertility, metabolic…
- Trial name
- NCT03135301
- Testing
- letrozole plus metformin, letrozole
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Assiut University
Estrogen Receptor Positive, Postmenopausal
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
This phase II trial studies how well ribociclib and letrozole work in treating patients with estrogen receptor (ER) positive ovarian, fallopian tube, primary peritoneal, or endometrial cancer that has returned (come back) after a…
- Conditions
- Estrogen Receptor Positive, Postmenopausal, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02657928
- Testing
- Laboratory Biomarker Analysis, Letrozole, Ribociclib
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Recurrent Breast Cancer, Stage IA Breast Cancer
Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole
This randomized pilot trial studies omega-3 fatty acid in preventing joint symptoms in patients with stage I-III breast cancer receiving anastrozole, exemestane, or letrozole.
- Conditions
- Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT01478477
- Testing
- omega-3 fatty acid supplement, Clinical assessments, Assessment of therapy complications
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Ectopic Pregnancy
Use of Letrozole for Ectopic Pregnancy
A randomized clinical trial using oral letrozole 10mg/day for 7 days, for treating early cases of ectopic pregnancy, compared to intramuscular methotrexate
- Trial name
- EcZOL (NCT06354439)
- Testing
- Letrozole tablets, Methotrexate Sodium
- Where
- Brazil
- Volunteers
- 130 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Uterine Leiomyosarcoma
Letrozole in Uterine Leiomyosarcoma
This is a clinical trial to test letrozole in patients with uterine leiomyosarcoma. The main question is will treatment with letrozole extend progression-free survival in patients. Patients will receive 2/5 mg of letrozole daily.
- Trial name
- NCT05649956
- Testing
- Letrozole
- Where
- 34 sites in United States
- Volunteers
- 40 people
- Sponsor
- GOG Foundation
Breast Neoplasms
GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer
Primarily to evaluate the rates of clinical and radiological response in the 2 groups. Secondarily rate of histological response.
- Trial name
- NCT00617968
- Testing
- DOCETAXEL
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Sanofi
Breast Cancer
Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00101062
- Testing
- celecoxib, letrozole
- Where
- United States
- Sponsor
- University of Medicine and Dentistry of New Jersey
Breast Carcinoma
Phase II Study of AS1402 Combined With Letrozole to Treat Breast Cancer
The aim of this study is to compare the overall tumour response rate per RECIST in postmenopausal women with metastatic or locally advanced breast cancer receiving AS1402 in combination with letrozole compared to letrozole alone
- Trial name
- NCT00770354
- Testing
- AS1402, Letrozole
- Where
- 2 sites in Russia
- Volunteers
- 110 people
- Sponsor
- Antisoma Research
Recurrent and Metastatic Endometrial Cancer
A Study of Letrozole in the Treatment of Endometrial Cancer
Currently available treatments for endometrial cancer are associated with limited efficacy and significant toxicity. This study will assess the safety and efficacy of letrozole, an aromatase inhibitor, on endometrial cancer.
- Trial name
- NCT00333086
- Testing
- Letrozole
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers
This study will assess optimal duration of pre-operative treatment with letrozole and to correlate clinical efficacy with appropriate surrogate markers.
- Trial name
- NCT00535418
- Testing
- Letrozole
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -
This is an international, multicenter, open-label, non-comparative, Simon´s two-stage design, phase II clinical trial.
- Trial name
- DxCARTES (NCT03819010)
- Testing
- Pre treatment Recurrence Score:18-25 Letrozole + Palbociclib, Pre treatment Recurrence Score:26-100 Letrozole + Palbociclib
- Where
- 18 sites in Portugal, Spain
- Volunteers
- 66 people
- Sponsor
- MedSIR